L
LB PHARMACEUTICALS INC
LBRXCIK 0001691082NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-25.20M
Total Assets
$312.93M
Equity
$301.31M
Shares Out
28.67M
Op. Cash Flow
$-35.20M
Business
LB PHARMACEUTICALS INC is a publicly listed company in Pharmaceutical Preparations, incorporated in Delaware. Common stock trades on Nasdaq under the ticker LBRX.
Auto-generated from company profile
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 |
|---|---|---|---|
| Research and development | 17 | 51 | |
| General and administrative | 14 | 14 | |
| Total operating loss | −30 | −65 | |
| Interest income | 4 | 2 | |
| Realized gain on sale of marketable securities, net | 119,000 | 955,000 | |
| Gain (loss) on change in fair value of derivative instruments | 1 | −947,000 | |
| Total non-operating income | 5 | 2 | |
| Loss before income tax | −25 | −63 | |
| Income tax provision | 1,000 | 1,000 | |
| Net loss | −25 | −63 | |
| Net loss per share, basic | −3.13 | −176.15 | |
| Net loss per share, diluted | −3.13 | −176.15 | |
| Weighted average shares outstanding used in calculating net loss per share, basic | 8 | 358,229 | |
| Weighted average shares outstanding used in calculating net loss per share, diluted | 8 | 358,229 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2025 2025-09-30 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 250 | — | 23 | — | |
| Marketable securities | 45 | — | 5 | — | |
| Prepaid expenses and other current assets | 13 | — | 880,000 | — | |
| Total current assets | 308 | — | 29 | — | |
| Operating lease right-of-use assets, net | 2 | — | 2 | — | |
| Property and equipment, net | 2 | — | 2 | — | |
| Restricted cash | 770,000 | — | 498,000 | — | |
| Total assets | 313 | — | 34 | — | |
| Accounts payable | 2 | — | 2 | — | |
| Accrued expenses | 5 | — | 5 | — | |
| Operating lease liability, current | 730,000 | — | 487,000 | — | |
| Total current liabilities | 7 | — | 8 | — | |
| Derivative liability - warrants | 1 | — | 3 | — | |
| Operating lease liability, noncurrent | 3 | — | 3 | — | |
| Total liabilities | 12 | — | 14 | — | |
| Commitments and contingencies (Note 13) | — | — | — | — | |
| Common stock, $0.0001 par value, 500,000,000 and 105,000,000 shares authorized, 25,299,372 and 251,655 shares issued and outstanding as of December 31, 2025 and 2024, respectively. | 3,000 | 114 | 1,000 | — | |
| Additional paid-in capital | 431 | — | 10 | — | |
| Accumulated deficit | −130 | — | −104 | — | |
| Accumulated other comprehensive income | 168,000 | — | 111,000 | — | |
| Total stockholders' equity (deficit) | 301 | — | −95 | −34 | |
| Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) | 313 | — | 34 | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 |
|---|---|---|---|
| Stock-based compensation expense | 4 | 3 | |
| Shares issued for services rendered | 0 | 71,000 | |
| Loss on write off of property and equipment | 8,000 | 0 | |
| Write off of deferred offering costs | 0 | 3 | |
| Depreciation and amortization | 321,000 | 91,000 | |
| Noncash lease expense | 147,000 | 308,000 | |
| Realized gain on sale of marketable securities, net | −119,000 | −955,000 | |
| Amortization (accretion) of premiums (discounts) on investments, net | 261,000 | −34,000 | |
| (Gain) loss on change in fair value of derivative instruments | −1 | 947,000 | |
| Prepaid expenses and other current assets | −12 | −2 | |
| Operating lease liability | −134,000 | −60,000 | |
| Accrued interest on marketable securities | −268,000 | 114,000 | |
| Accounts payable and accrued expenses | −910,000 | 5 | |
| Net cash used in operating activities | −35 | −53 | |
| Purchases of property and equipment | −52,000 | −769,000 | |
| Purchase of marketable securities | −45 | −30 | |
| Proceeds from the sale of marketable securities | 3 | 24 | |
| Maturities of marketable securities | 3 | 30 | |
| Net cash (used in) provided by investing activities | −40 | 23 | |
| Proceeds from initial public offering | 328 | 0 | |
| Payment of issuance costs for initial public offering | −25 | 0 | |
| Proceeds from exercise of warrants and options | 247,000 | 23,000 | |
| Proceeds from issuance of redeemable convertible Series C preferred stock | 0 | 40 | |
| Payment of issuance costs for redeemable convertible Series C preferred stock | 0 | −2 | |
| Net cash provided by financing activities | 303 | 38 | |
| Net increase in cash, cash equivalents and restricted cash | 227 | 8 | |
| Income tax paid | 1,000 | 1,000 | |
| Conversion of 78,072,306 shares (1) of redeemable convertible preferred stock to common stock upon the closing of initial public offering | 114 | 0 | |
| Right of use assets in exchange for operating lease liabilities | 0 | 2 | |
| Acquisition of leasehold improvements | 0 | 1 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro